Tech Center 1600 • Art Units: 1627
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17916467 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18275388 | METHODS FOR TREATING AND AMELIORATING CANCER | Non-Final OA | The Regents of the University of California |
| 17928496 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18033178 | METHODS TO SENSITIZE TUMORS TO TREATMENT BY IMMUNOTHERAPY | Final Rejection | Ohio State Innovation Foundation |
| 18255339 | COMPOUNDS FOR THE TREATMENT OF SARS | Non-Final OA | Purdue Research Foundation |
| 18257677 | SELECTIVE HDAC6 INHIBITOR | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18563575 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | Non-Final OA | The General Hospital Corporation |
| 18265030 | METHOD OF TREATING AND PREVENTING VIRAL INFECTION | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 17919726 | COMBINATION THERAPY OF ARTEMISININ-RELATED COMPOUNDS AND HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF HPV-RELATED BENIGN, PREMALIGNANT, AND MALIGNANT DISEASES | Non-Final OA | Georgetown University |
| 18220090 | INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18269086 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Non-Final OA | BIOGEN MA INC. |
| 18268440 | SUBSTITUTED INDOLE COMPOUNDS | Final Rejection | Gilead Sciences, Inc. |
| 18627415 | Treatment of Respiratory Diseases | Non-Final OA | TIANLI BIOTECH PTY LTD |
| 18560341 | RESCORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18114979 | AMINO ACID COMPOUNDS AND METHODS OF USE | Non-Final OA | Pliant Therapeutics, Inc. |
| 17633128 | COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | Non-Final OA | INSTITUT CURIE |
| 18458604 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | Non-Final OA | Ankh Life Sciences Limited |
| 18236560 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | Non-Final OA | ENANTA PHARMACEUTICALS, INC. |
| 18259306 | PYRIMIDO-HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | SHANGHAI RINGENE BIOPHARMA CO., LTD. |
| 17760329 | USP7 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | ALMAC DISCOVERY LIMITED |
| 17998445 | PREPARATION OF BIARYL RING-LINKED AROMATIC HETEROCYCLIC DERIVATIVE AS IMMUNOMODULATOR AND USE THEREOF | Non-Final OA | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. |
| 18039895 | GPX4 PROTEIN DEGRADATION-INDUCING COMPOUND | Non-Final OA | UPPTHERA |
| 18325930 | CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL ADJUVANT THERAPIES | Final Rejection | CytoAgents, Inc. |
| 18314047 | NALTREXONE AND RISPERIDONE COMBINATION SUSTAINED-RELEASE COMPOSITION | Final Rejection | SHENZHEN SCIENCARE MEDICAL INDUSTRIES CO., |
| 18250738 | 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER | Final Rejection | GODAVARI BIOREFINERIES LIMITED |
| 17606003 | COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION | Final Rejection | INMED PHARMACEUTICALS INC. |
| 18022254 | METHODS AND USES OF HALOFUGINONE | Final Rejection | Daniel R. SANDOVAL |
| 17995947 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Non-Final OA | CHONG KUN DANG PHARMACEUTICAL CORP. |
| 17970293 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | Non-Final OA | ENDECE LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy